ClinicalTrials.gg
RecruitingNCT06647901Updated Oct 18, 2024

Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study

A Phase 1/2 interventional study of ICG (Indocyanine Green) in Giant Cell Tumor of Bone, sponsored by Tang Xiaodong. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-18.

Sponsored by Tang Xiaodong · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.
Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

ICG fluorescence imaging will be applied during the intralesional curettage of giant cell tumor of bone in the limbs. This study aims to preliminarily explore whether ICG fluorescent-guided curettage could find small residual tumors and reduce the recurrence rate of tumor.

Read the detailed description

Recurrence is a problem in the treatment of giant cell tumor of bone(GCTB). With the application of high-speed burr and other adjuvant therapy (phenol, liquid nitrogen freezing, cauterization, etc.), the recurrence rate is greatly reduced, but it is still as high as 20%. The main cause of local recurrence is the difficulty in distinguishing small residual tumor lesions by the naked eye. The application of frozen section is limited due to the long-term decalcification of bone specimens.

Intraoperative near-infrared (NIR) imaging is a promising technology expected to solve the above problems. It allows for real-time scanning of a wide area with tumor showing fluorescence. Such intraoperative fluorescent signals provide objective evidence for the surgeon and are more reliable than subjective visual and tactile information.

This study aims to explore whether ICG-based NIR imaging guided curettage could find small residual tumors and reduce the recurrence rate of GCT.

02

Conditions studied

  • Giant Cell Tumor of Bone

Keywords

  • ICG
  • Giant cell tumor of bone
  • curettage
03

In context

Giant Cell Tumor of Bone

23 studies on the registry are indexed under Giant Cell Tumor of Bone; 7 are open to participants now.

This study's planned enrollment of 45 is close to the median of 43 across 16 interventional studies indexed under Giant Cell Tumor of Bone.

Browse Giant Cell Tumor of Bone studies →

Lead sponsor

Tang Xiaodong is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. . Aged 18-65.
  2. confirmed giant cell tumor of bone.
  3. The lesions located in the limbs.
  4. This operation is the initial treatment.
  5. Denosumab and diphosphonates are not used before surgery.
  6. Planned operation is intralesional curettage and filling bone defects with bone cement.
  7. Preoperative bone scan and thin layer (layer thickness ≤3.5mm) chest CT plain scan confirmed that the lesion is a single occurrence without .
  8. Subjects fully understand the benefits and risks of this experiment and are still willing to participate and sign the .

Exclusion criteria

Exclusion Criteria:

  1. . Known allergy to iodine contrast, indocyanine green or bone cement.
  2. . Severe hepatic and renal insufficiency.
  3. . During pregnancy or lactation.
  4. . Have other malignant tumors and are receiving related medical treatment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    ICG group

    Drug: ICG (Indocyanine Green)

Interventions

  • Patients will be receive intravenously administrated at a dose of 2 mg/kg on the day before surgery. The drug was dissolved into 250 mL of normal saline and administered using a light-proof infusion apparatus. The time course of administration was 60 min. NIR imaging will be performed during surgery to help identify small tumor residuals.

06

What researchers measure

Primary outcomes

  1. local recurrence rate of tumor

    To explore whether based on ICG-based-NIR fluorescence imaging assisted intralesional curettage can reduce the local recurrence rate of giant cell tumor of bone in limbs.

    Time frame: From surgery to 2 years after surgery

Secondary outcomes

  1. Accuracy of ICG prediction tumor residuals

    To explore the accuracy of ICG fluorescence in detection of small residual tumor lesions and calculate the sensitivity, specificity, positive predictive value, negative predictive value.

    Time frame: From surgery to 2 weeks after surgery

  2. Correlation between fluorescence intensity and pathology findings of tumor residuals

    To explore the correlation between ICG fluorescence intensity and accuracy of detection of residual tumor lesions.

    Time frame: From surgery to 2 weeks after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06647901
Lead sponsor
Tang Xiaodong
Responsible party
Tang Xiaodong (Dr., Peking University People's Hospital) — Sponsor-investigator
First posted
Oct 18, 2024
Start date
Aug 23, 2024
Primary completion
Aug 31, 2026 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Oct 18, 2024

Study contacts

Han Wang, MD
Contact
wh23333@126.com
+86 13520170664
Xiaodong Tang, MD
Contact
tang15877@126.com
+86 8832 6150

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Indocyanine Green

Start the discussion